Skip to main content

Table 1 Demographics and clinical features of the patient cohort

From: Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Demographics AD DLB OND PD PDD p Value
N 48 40 46 54 20  
Sex, male, n (%) 23 (47.9) 27 (67.5) 18 (39.1) 35 (64.8) 13 (65.0) 0.026
Age, years 70.9 (9.6) 73.1 (6.3) 58.6 (17.3) 66.0 (8.9) 73.7 (5.7) <0.001
MMSE score 18.4 (5.2) 19.2 (5.5) 26.7 (4.3) 27.8 (2.2) 19.2 (4.4) <0.001
MoCA score 25.5 (3.3)
UPDRS-III score 27.9 (12.5) 24.3 (12.9) 33.3 (15.9) 0.092
H&Y score 3.0 (0.7) 1.7 (0.5) 3.6 (1.1) <0.001
Center Perugia 20 Kassel, 20 Antwerp Perugia Perugia 19 Kassel, 1 Perugia  
  1. Abbreviations: AD Alzheimer’s disease, DLB Dementia with Lewy bodies, H&Y Hoehn & Yahr, MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, UPDRS-III Unified Parkinson’s Disease Rating Scale part III
  2. The number of patients included in each group, age, and sex, together with cognitive and motor scores, are reported. All data are reported using mean (SD), with the exception of the number of male patients, which is reported as a percentage. The p value is relative to the nonparametric analysis of variance test for the overall difference among the groups